What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...

Right up front in its proxy filing with the SEC, Eli Lilly took care of justifying its $36.7 mill | With sales booming at Eli Lilly, the Indianapolis company has compensated CEO David Ricks with a $36 ...

Spruce Biosciences has named Dale Hooks chief commercial officer, securing a leader with experience launching 21 products as the company heads toward a filing for its first FDA approval.

Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.

Hims & Hers and Novo Nordisk have officially laid down their swords. | The agreement marks the end of a longstanding public feud and allows Hims & Hers to sell Novo's branded Ozempic and Wegovy on its ...

In 2019, BMS made a big bet on Sotyktu by deciding to keep the then-pipeline asset despite its pending acquisition of Celgene. Based on that decision, BMS sold its mega-blockbuster Otezla to Amgen for ...

Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.